Blue Earth Diagnostics

Blue Earth Diagnostics company information, Employees & Contact Information

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Company Details

Employees
103
Founded
-
Address
Magdalen Centre, The Oxford Science Park,united States
Phone
4401865784186
Email
co****@****hDx.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Oxford
Looking for a particular Blue Earth Diagnostics employee's phone or email?

Blue Earth Diagnostics Questions

News

Blue Earth Diagnostics, a Bracco Company, Applauds New CMS Rule to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals - Business Wire

Blue Earth Diagnostics, a Bracco Company, Applauds New CMS Rule to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals Business Wire

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting - Imaging Technology News

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting Imaging Technology News

Philochem and Blue Earth Diagnostics Announce First Three - GlobeNewswire

Philochem and Blue Earth Diagnostics Announce First Three GlobeNewswire

Bracco to acquire Blue Earth Diagnostics - AuntMinnie

Bracco to acquire Blue Earth Diagnostics AuntMinnie

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Company’s Next Phase of Business Growth - Business Wire

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Company’s Next Phase of Business Growth Business Wire

Blue Earth Diagnostics sold to Bracco Imaging in $450M deal - Fierce Biotech

Blue Earth Diagnostics sold to Bracco Imaging in $450M deal Fierce Biotech

GE Healthcare, Blue Earth Diagnostics ink UK manufacturing deal - Drug Delivery Business

GE Healthcare, Blue Earth Diagnostics ink UK manufacturing deal Drug Delivery Business

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases - Imaging Technology News

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases Imaging Technology News

Blue Earth Diagnostics, a Bracco Company, Lauds CMS Proposal to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals - Business Wire

Blue Earth Diagnostics, a Bracco Company, Lauds CMS Proposal to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals Business Wire

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer - Imaging Technology News

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer Imaging Technology News

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA - Business Wire

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA Business Wire

Axumin PET Injection Now Commercially Available in United States - Imaging Technology News

Axumin PET Injection Now Commercially Available in United States Imaging Technology News

Blue Earth Diagnostics Announces CMS Transitional Pass-Through Payment Reimbursement Code for POSLUMA® (Flotufolastat F 18) Injection, Effective October 1, 2023 - Business Wire

Blue Earth Diagnostics Announces CMS Transitional Pass-Through Payment Reimbursement Code for POSLUMA® (Flotufolastat F 18) Injection, Effective October 1, 2023 Business Wire

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer - Imaging Technology News

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer Imaging Technology News

Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA® (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer - Business Wire

Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA® (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer Business Wire

Axumin (Fluciclovine F-18) PET Tracer Effective in Detecting Recurrent Prostate Cancer - Imaging Technology News

Axumin (Fluciclovine F-18) PET Tracer Effective in Detecting Recurrent Prostate Cancer Imaging Technology News

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer - Business Wire

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer Business Wire

(Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer - Business Wire

(Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer Business Wire

Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA® (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer - Business Wire

Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA® (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer Business Wire

Helen Barker joins Blue Earth Diagnostics - PharmaTimes

Helen Barker joins Blue Earth Diagnostics PharmaTimes

Top Blue Earth Diagnostics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant